Miscellaneous Adverse Events with Biologic Agents (Excludes Infection and Malignancy) - 09/08/14
Résumé |
Anti-tumor necrosis factor-α (anti-TNF) agents are frequently used in the treatment of inflammatory bowel disease (IBD). Currently, there are 4 anti-TNF therapies that are Food and Drug Administration–approved for moderate to severe IBD: infliximab, adalimumab, golimumab, and certolizumab pegol. For most noninfectious, nonmalignant adverse events, cessation of anti-TNF therapy typically leads to improvement or resolution of drug-induced complications. In this article, the current knowledge regarding the noninfectious and nonmalignant toxicities associated with anti-TNF agents is summarized.
Le texte complet de cet article est disponible en PDF.Keywords : Anti-tumor necrosis factor, Infliximab, Adalimumab, Golimumab, Certolizumab pegol, Complications, Infusion reactions, Autoimmune disease
Plan
Vol 43 - N° 3
P. 543-563 - septembre 2014 Retour au numéro
Article précédent
- The Risk of Malignancy Associated with the Use of Biological Agents in Patients with Inflammatory Bowel Disease
- Parambir S. Dulai, Corey A. Siegel
- Pharmacokinetics of Biologics and the Role of Therapeutic Monitoring
- Kirk Lin, Uma Mahadevan
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?